Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. Their therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 26, 2022 | Series B | $85M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Intellia Therapeutics | — | Series B |
jVen Capital | — | Series B |